What is Nostos Genomics?
Nostos Genomics operates at the intersection of artificial intelligence and genomics, aiming to revolutionize the understanding and treatment of genetic diseases. The company's proprietary genetic variant interpretation platform, AION, employs advanced machine learning algorithms and functional genomics to accurately characterize mutations. This sophisticated approach automates the complex process of genetic interpretation, paving the way for more impactful clinical applications and personalized medicine.
How much funding has Nostos Genomics raised?
Nostos Genomics has raised a total of $5.7M across 1 funding round:
Angel/Seed
$5.7M
Angel/Seed (2022): $5.7M with participation from 42cap, Acequia Capital, Entrepreneur First, Amino Collective, and Frontline Ventures
Key Investors in Nostos Genomics
42cap
42CAP is a venture capital firm specializing in seed-stage tech and data-driven B2B software companies, focusing on empowering entrepreneurs with innovative solutions.
Acequia Capital
Acequia Capital is a venture capital firm that invests in early-stage technology companies, particularly those with disruptive potential.
Entrepreneur First
Entrepreneur First is an international Talent Investor that supports individuals in building technology companies, fostering innovation from inception.
What's next for Nostos Genomics?
The recent major strategic investment signifies a pivotal moment for Nostos Genomics, likely positioning the company for accelerated scaling and further development of its AI-powered genomic interpretation capabilities. This infusion of capital is expected to bolster research and development efforts, expand market reach, and potentially forge new clinical partnerships. The company's trajectory suggests a focus on solidifying its position as a leader in the burgeoning field of precision medicine, leveraging its technological edge to address unmet needs in genetic diagnostics and therapeutics.
See full Nostos Genomics company page
